Elena Ho
Publications by Year
Research Areas
Blood Coagulation and Thrombosis Mechanisms, Hemophilia Treatment and Research, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Protease and Inhibitor Mechanisms, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1(2000)208 cited
- → Differential Inhibition of Inducible T Cell Cytokine Secretion by Potent Iron Chelators(2005)97 cited
- → Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro- 6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycine (ZK-807834): A Potent, Selective, and Orally Active Inhibitor of the Blood Coagulation Enzyme Factor Xa(1998)63 cited
- → Measurements of drug–protein binding by using immobilized human serum albumin liquid chromatography–mass spectrometry(2004)53 cited
- → Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: Design, synthesis and biological activity(2007)50 cited
- → Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517(2007)42 cited
- → Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys(2017)41 cited
- → von Willebrand factor contributes to longer half‐life of PEGylated factor VIII in vivo(2013)30 cited
- → Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa(2006)24 cited
- → Design, Synthesis, and Activity of a Novel Series of Factor Xa Inhibitors: Optimization of Arylamidine Groups(2002)20 cited